Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427 lmelens@lifespring.nl
- - Corporate Communications
- - Healthcare PR
- - Financial Communications
- - Content Marketing
- - Social Media and Online Communications
Paris, France and Amsterdam, The Netherlands, 9 December 2020 – Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS)
Reference is made to the joint press release by Sanofi and Kiadis dated 2 November 2020 in respect of the Offer to be made by Sanofi at an offer price of EUR 5.45 in cash per share (cum dividend).
Sanofi and Kiadis confirm that they are making good progress on the preparations for the Offer. As announced on 30 November 2020, the Offer Document in relation to the Offer was filed with the AFM on 30 November 2020 and is under review.
Today, Sanofi and Kiadis jointly announce that the competition condition for completion of the Offer as announced in the press release of 2 November 2020, has now been satisfied.
Sanofi and Kiadis anticipate that the Offer will close in the first half of 2021.
Science Park 400 Matrix II Building 1098 XH Amsterdam +31 (0)653816427 lmelens@lifespring.nl